The diagnostic yield of hereditary cancer genetic testing has improved over time as new technologies have been established. Despite these improvements, a substantial proportion of patients undergoing DNA testing for hereditary cancer still either receive inconclusive results or remain without a molecular diagnosis. This webinar will demonstrate how concurrent DNA and RNA genetic testing increases detection of clinically- actionable variants and reduces variants of unknown significance (VUS), ultimately improving the positive yield of genetic testing.